Molecular Partners (MOLN) Stock: Buy, Sell, or Hold?
MOLN - Molecular Partners AG American Depositary Shares
$3.64
0.03 (0.85%)
▲
5d:
+2.25%
30d:
-13.33%
90d:
-8.08%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 29, 2026
5d
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $3.64, which is considered oversold relative to its 30-day fair value range of $3.66 to $4.08. From a valuation perspective, the stock is trading at a discount (Forward PE: -26.5) compared to its historical average (31.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is showing sideways momentum. Immediate support is located at $3.52, while resistance sits at $3.88.
Market Sentiment: MOLN scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.53 (+191.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MOLN is showing sideways momentum. Immediate support is located at $3.52, while resistance sits at $3.88.
Market Sentiment: MOLN scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.53 (+191.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.66 -
$4.08
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 191.9% below Wall St target ($10.53)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 84/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.66 -
$4.08
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.52
Resistance Level
$3.88
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.54
Wall Street Target
$10.53
(+191.9%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-26.5 vs 31.9
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 9:54 AM ET
Data refreshes hourly during market hours. Next update: 10:54 AM
Data refreshes hourly during market hours. Next update: 10:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 63 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 63 BUY |
